Cargando…

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action

BACKGROUND: The presence of lupus anticoagulant (LA) is an independent risk factor for thrombosis. This laboratory phenomenon is detected as a phospholipid‐dependent prolongation of the clotting time and is caused by autoantibodies against beta2‐glycoprotein I (β2GPI) or prothrombin. How these autoa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noordermeer, Tessa, Molhoek, Jessica E., Schutgens, Roger E. G., Sebastian, Silvie A. E., Drost‐Verhoef, Sandra, van Wesel, Annet C. W., de Groot, Philip G., Meijers, Joost C. M., Urbanus, Rolf T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048633/ https://www.ncbi.nlm.nih.gov/pubmed/33421291 http://dx.doi.org/10.1111/jth.15241

Ejemplares similares

Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen
por: Bar Barroeta, Awital, et al.
Publicado: (2022)

Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate
por: Bavalia, Roisin, et al.
Publicado: (2020)

Interference in point-of-care international normalized ratio monitoring in patients with lupus anticoagulant is correlated with anti–β2-glycoprotein I antibody titers
por: Noordermeer, Tessa, et al.
Publicado: (2022)

Paving the way for establishing a reference measurement system for standardization of plasma prothrombin time: Harmonizing the manual tilt tube method
por: van den Besselaar, Antonius M. H. P., et al.
Publicado: (2020)

Mapping the prothrombin-binding site of pseutarin C by site-directed PEGylation
por: Üstok, Fatma Işık, et al.
Publicado: (2022)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Prevalence, burden and treatment effects of vaginal bleeding in women with (suspected) congenital platelet disorders throughout life: a cross‐sectional study
por: Punt, Marieke C., et al.
Publicado: (2021)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

The development and characterization of a long acting anti‐thrombotic von Willebrand factor (VWF) aptamer
por: Zhu, Shuhao, et al.
Publicado: (2020)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk
por: Egri, Natalia, et al.
Publicado: (2021)

Ruling out lupus anticoagulants with mixing test–specific cutoff assessment and the index of circulating anticoagulant
por: Kumano, Osamu, et al.
Publicado: (2019)

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples
por: Baker, Steven Andrew, et al.
Publicado: (2021)

Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study
por: Sciascia, Savino, et al.
Publicado: (2019)

Histidine-rich glycoprotein attenuates catheter thrombosis
por: Malik, Rida A., et al.
Publicado: (2023)

Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study
por: Noordermeer, Tessa, et al.
Publicado: (2022)

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
por: Lu, Genmin, et al.
Publicado: (2020)

Concomitant appearance of anti-cardiolipin, anti-β(2)-glycoprotein I, anti-prothrombin and anti-annexin V antibodies
por: Cucnik, S, et al.
Publicado: (2004)

Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE
por: Cohen, Omri, et al.
Publicado: (2021)

Monoclonal and Oligoclonal Anti-PF4 Antibodies Mediate VITT
por: Singh, Bandana, et al.
Publicado: (2021)

Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia
por: Tuleja, Aleksandra, et al.
Publicado: (2022)

Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant
por: Kumano, Osamu, et al.
Publicado: (2017)

The Impact of Degree of Anticoagulation on Thrombotic and Other Complications in Hospitalized COVID-19 Patients
por: Zheng, Rena, et al.
Publicado: (2021)

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
por: Carney, Brian J., et al.
Publicado: (2021)

Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis
por: Candeloro, Matteo, et al.
Publicado: (2022)

Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population
por: Raskob, Gary E., et al.
Publicado: (2022)

Structure of coagulation factor VIII bound to a patient-derived anti–C1 domain antibody inhibitor
por: Childers, Kenneth C., et al.
Publicado: (2023)

Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?
por: Pratt, Kathleen P., et al.
Publicado: (2022)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation
por: Andrade, S.A., et al.
Publicado: (2012)

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient
por: Schönborn, Linda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0m04mhaafpfc0ne665po85tt22